Navigation Links
Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance
Date:1/5/2012

INDIANAPOLIS, Jan. 5, 2012 /PRNewswire/ --

  • Company expects to meet or exceed 2011 EPS guidance.
  • 2012 financial guidance reflects revenue and earnings declines due to Zyprexa patent expiration.
  • 2012 revenue anticipated to be between $21.8 billion and $22.8 billion.
  • Company expects to keep 2012 operating expenses essentially flat versus 2011.
  • 2012 earnings per share forecasted to be in the range of $3.10 - $3.20.
  • R&D pipeline includes 12 molecules in Phase III development at end of 2011, exceeding goal of 10.
  • Mid-term guidance through 2014 reconfirmed with minimum annual results of at least $20 billion in revenue, $3 billion in net income and $4 billion in operating cash flow.
  • Company reaffirms commitment to fund dividend at least at current level.

Eli Lilly and Company (NYSE: LLY) today commented on its 2011 financial guidance and announced its financial guidance for 2012. The company also reconfirmed its mid-term guidance through 2014.

For 2011, the company expects to meet or exceed its current earnings per share guidance. 2011 EPS guidance is currently in the range of $3.84 to $3.89 on a reported basis, or $4.30 to $4.35 on a non-GAAP basis when excluding $.23 of in-process research and development charges associated with the Boehringer Ingelheim collaboration and $.18 of asset impairment and restructuring charges through the first nine months of 2011, as well as an estimated $.05 asset impairment charge in the fourth quarter of 2011 related to the Xigris® withdrawal. For 2012, the company expects earnings per share to be in the range of $3.10 to $3.20 on both a reported and non-GAAP basis.

"2012 is an important year for Lilly, having entered the period when we face patent expirat
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... FRANCISCO , Aug. 3, 2015  Sage Analytics ... of portable laboratory-quality cannabis potency measurement systems, announced its ... Bay Area Cruise Fundraiser. A limited number of tickets ... festivities and help a great cause while enjoying an ... scenic cruise around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... FRANCISCO , August 3, 2015 ... size is expected to reach USD 24.7 billion ... Grand View Research Inc. Growing prevalence of neurological ... physiotherapy equipments market over the forecast period. The ... ultrasound and cryotherapy, advancement in the technologies coupled ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... System as a non-invasive, wireless, transdermal continuous glucose monitoring ... delivery, today announced that it has raised approximately $2.5 ... Company,s stock and warrants, and it has received a ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... January 13th at 11:30 a.m. PST. (Logo:   ... or the subsequent archived recording, log on to www.rigel.com ...
Cached Medicine Technology:Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 2Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 3Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 4
(Date:8/3/2015)... Ore. (PRWEB) , ... August 03, 2015 , ... They ... Providence St. Vincent Medical Center offers some of the best care in ... M.D., neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that ... Medical Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Inc.,(Nasdaq: ATRC ), a medical device company ... announced that its minimally invasive platform was,highlighted during ... techniques. On June 18, Dr. Kenneth,Ellenbogen, Vice Chairman ... Pacing at the Medical College of Virginia, chaired ...
... on MRIs with limited side effects, study found , , FRIDAY, ... to treat the "relapse-remitting" form of multiple sclerosis has been ... , Although the drug, laquinimod, is still experimental, having a ... patients. , "By and large, this doesn,t look as strong ...
... PRGO ; TASE) today announced that it ... Drug Administration to manufacture and market,Cetirizine Hydrochloride Syrup ... Consumer Healthcare,s Zyrtec(R) Syrup, 1mg/mL, indicated for the,relief ... Perrigo,s Chairman and CEO Joseph C. Papa stated, ...
... no added benefit , , THURSDAY, June 19 (HealthDay News) ... risk of HIV-1 infection in people who have sex ... finds. , Previous research has shown that herpes simplex ... of genital herpes -- increases the risk for HIV-1 ...
... Bills Delay and Fix Competitive Bidding System for ... Pete Stark,(D-CA), chair of the House Ways & ... DMEPOS Competitive Acquisition Reform,Act of 2008. Sens. Max ... member of the Senate Finance Committee, have introduced ...
... The results of a major international clinical trial coordinated ... the New England Journal of Medicine . The ... a prospective, multicentre project involving patients with heart failure ... of death in the population and associated atrial fibrillation ...
Cached Medicine News:Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 2Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 3Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 4Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3
Swedish Knee Cage -- hinged to track knee motion. Effective control of genu recurvatum (back knee or knee hyperextension). Fits left or right....
... The Infrapatellar Band uses an ... the patellar tendon helping to ... and patella tendonitis. Focusing the ... tibial tubercle with less constriction ...
Designed to provide continuous cold therapy to the shoulder and back. Helps to reduce pain and swelling and speed rehab....
... immobilization following shoulder fusion, dislocation, reconstruction ... allows the shoulder to be positioned ... Following brachial plexus injury this orthosis ... stretch during the healing process and ...
Medicine Products: